| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HIV.12401 |
| P698 | PubMed publication ID | 26952360 |
| P2093 | author name string | P Mallon | |
| A Antela | |||
| J Compston | |||
| M Boffito | |||
| B M Hendry | |||
| C Aguiar | |||
| G Di Perri | |||
| V Pourcher-Martinez | |||
| P2860 | cites work | Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals | Q22242705 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro | Q24633870 | ||
| HIV infection and cardiovascular disease | Q27008915 | ||
| HIV infection and the risk of acute myocardial infarction | Q27347231 | ||
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
| The end of AIDS: HIV infection as a chronic disease | Q28300749 | ||
| Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada | Q28537704 | ||
| Redefining the HIV epidemic in Nigeria: from national to state level | Q30602887 | ||
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 | ||
| Incident fractures in HIV-infected individuals: a systematic review and meta-analysis | Q33648297 | ||
| Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue | Q33769993 | ||
| The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment | Q33813372 | ||
| HIV Infection, Inflammation, Immunosenescence, and Aging | Q34150710 | ||
| Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. | Q34405742 | ||
| Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study | Q34691316 | ||
| Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o | Q35000905 | ||
| The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection | Q35019915 | ||
| Acceleration of age-associated methylation patterns in HIV-1-infected adults | Q35217255 | ||
| Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles | Q35393050 | ||
| Future challenges for clinical care of an ageing population infected with HIV: a modelling study | Q35925654 | ||
| Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system | Q36938343 | ||
| Cost of noninfectious comorbidities in patients with HIV. | Q37213494 | ||
| HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity | Q37378238 | ||
| Defeating AIDS--advancing global health | Q38539190 | ||
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. | Q40100382 | ||
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study | Q40922158 | ||
| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials | Q41044551 | ||
| Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study | Q41266838 | ||
| Tenofovir alafenamide for HIV infection: is less more? | Q41311570 | ||
| Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies | Q41643193 | ||
| Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. | Q41725190 | ||
| Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. | Q41984465 | ||
| Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration | Q42205361 | ||
| Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study | Q42213339 | ||
| Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults | Q42287616 | ||
| Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study | Q42912276 | ||
| Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients | Q43044739 | ||
| Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. | Q44068589 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Cancer risk in people infected with human immunodeficiency virus in the United States | Q45395561 | ||
| Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. | Q45836204 | ||
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d | Q45910955 | ||
| Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents | Q48738533 | ||
| P921 | main subject | tenofovir | Q155954 |
| P304 | page(s) | 4-16 | |
| P577 | publication date | 2016-03-08 | |
| P1433 | published in | HIV Medicine | Q15756376 |
| P1476 | title | The role of tenofovir alafenamide in future HIV management | |
| P478 | volume | 17 Suppl 2 |
| Q59353797 | Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection |
| Q40051462 | Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings. |
| Q61820482 | Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid |
| Q39170367 | Immunosenescence and hurdles in the clinical management of older HIV-patients |
| Q40099241 | Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate |
| Q89805585 | Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years |
| Q39453985 | Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence |
| Q57151247 | Perceived Stigma in People Living With HIV in Qom |
| Q38732666 | ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites |
| Q90329919 | Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid |
| Q37660709 | p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects |
Search more.